相关实验视频
Updated: Jul 11, 2025

06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
36.7K
神经性斑块 - 了解阿尔茨海默病的入口
Wangchen Tsering1,2,3, Stefan Prokop4,5,6,7
1Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, USA.
Molecular neurobiology
|November 8, 2023
概括
神经性斑块是阿尔茨海默病 (AD) 的关键特征,与认知能力下降有关. 了解它们的形成对于开发有效的针对粉样蛋白β (Aβ) 沉积的AD疗法至关重要.
科学领域:
- 神经科学是一个神经科学.
- 病理学 病理学 病理学
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 阿尔茨海默氏病 (AD) 的特征是细胞外粉样蛋白-β (Aβ) 斑块.
- 存在各种Aβ斑块形态,但它们与AD进展的相关性尚不清楚.
- 神经性斑块是一种特定的亚型,被缩性神经炎包围,被认为是非常有害的.
研究的目的:
- 对阿尔茨海默病中神经质斑块的当前知识进行审查.
- 突出神经质斑块作为由此产生的Aβ斑块形态学的重要性.
- 强调需要了解针对性AD疗法的神经性斑块形成的必要性.
主要方法:
- 对阿尔茨海默病中Aβ斑块形态现有研究的文献综述.
- 对与阿尔茨海默病症状和进展相关的斑块类型研究的分析.
- 综合有关神经斑块病理特征和后果的信息.
主要成果:
- 神经性斑块与局部免疫激活,神经网络功能障碍和认知能力下降有关.
- 这些斑块位于Aβ沉积,tau聚合和神经炎症的交叉点.
- 不同Aβ斑块亚型的发展的确切触发因素仍然未知.
结论:
- 神经性斑块是阿尔茨海默病中最有害的Aβ斑块形态.
- 了解神经质斑块的形成机制对于开发针对性AD治疗至关重要.
- 对神经斑块发育的进一步研究可能会导致AD的新治疗策略.
相关概念视频
Alzheimer's Disease: Overview
498
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
498
Alzheimer's Disease: Treatment
197
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
197
Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K
Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
Dementia
120
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
120
Parkinson's Disease: Overview
564
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
564

